Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$5.54
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.64%
Accommodative
10-Year Treasury
4.32%
2026-04-01
Unemployment
4.3%
Near full employment
CPI Index
332.4
2026-04-01
M2 Money Supply
$22.8T
2026-04-01
The Federal Funds rate stands at 3.64% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.32%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.3%; Industrial production index is at 102.5; M2 money supply is $22.8T; CPI index stands at 332.4.
SWOT Analysis — ARDX
Inflationary BoomStrengths
Gross Profit: $4.7M (+118.6% YoY) — Gross profit rose 119% — the spread between revenue and direct costs improved.
Total Assets: $501.6M (+15.1% YoY) — Total assets grew 15% — the company's resource base expanded.
Weaknesses
Revenue: $2.6M (-93.8% YoY) — Revenue fell 94% — the company generated less from its core operations.
Net Income: -$61.6M (-57.4% YoY) — The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted): $-0.26 (-52.9% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
R&D spending is 2744% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
No clear opportunities identified at this time.
Threats
Revenue fell 94% year-over-year — a sharp decline that signals the business is contracting significantly.
Net loss of $61.6M — the company spent more than it earned. Investors should monitor the path to profitability.
Negative operating cash flow of $42.5M — the core business consumed more cash than it generated.
Financial Charts
Revenue vs Net Income
Gross Profit vs Operating Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
Gross Profit
$4.7M
was $2.1M
Gross profit rose 119% — the spread between revenue and direct costs improved.
Revenue
$2.6M
was $42.0M
Revenue fell 94% — the company generated less from its core operations.
Net Income
-$61.6M
was -$39.1M
The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted)
$-0.26
was $-0.17
Negative EPS — the company recorded a loss on a per-share basis.
Total Assets
$501.6M
was $435.8M
Total assets grew 15% — the company's resource base expanded.
Risk Flags
3 high · 0 medium · 1 low- ⚠ High
Revenue fell 94% year-over-year — a sharp decline that signals the business is contracting significantly.
- ⚠ High
Net loss of $61.6M — the company spent more than it earned. Investors should monitor the path to profitability.
- ⚠ High
Negative operating cash flow of $42.5M — the core business consumed more cash than it generated.
- ○ Low
R&D spending is 2744% of revenue — heavy investment in future growth, but also a drag on current profitability.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade ARDX
Links open broker research pages. Not an endorsement or recommendation.
Research ARDELYX, INC.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.